PDE5A and hepatocellular carcinoma: One year later the same group reported that HCC treatment with a PDE5 inhibitor leads to transaminases and cholestasis enzymes restoration in serum, associated with normalization of mRNA expression of cancer-associated transcription factors such as c-Myc or Akt, of TGF-beta and angiogenesis markers such as HIF-1alpha and VEGF [77].